Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Breast Neoplasms 3Vulvar Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 3Cisplatin 3Capecitabine 3Trastuzumab 2Paclitaxel 2Irinotecan 2Docetaxel 2Carboplatin 2tivozanib 1tipifarnib 1seribantumab 1sargramostim 1lenvatinib 1entinostat 1atezolizumab 1Thalidomide 1Psychiatric Rehabilitation 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Nivolumab 1Mesna 1Magnetic Resonance Spectroscopy 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunohistochemistry 1Ifosfamide 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Fluorouracil 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × tivozanib × Breast × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡